Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 6 years or older.~* A confirmed diagnosis of HAE type I or II.~* HAE attacks over a consecutive 2-month period that required acute treatment, medical attention, or caused significant functional impairment.~* For subjects who have used oral therapy for prophylaxis against HAE attacks within 3 months of first study visit: use of a stable regimen within 3 months of the first study visit.~Exclusion Criteria:~* Incurable malignancies.~* Any clinical condition that will interfere with the evaluation of C1-INH therapy.~* Clinically significant history of poor response to C1-esterase therapy for the management of HAE.~* Suspected or confirmed diagnosis of acquired HAE or HAE with normal C1-INH.~* Inability to have HAE managed pharmacologically with on-demand treatment.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C1-INH - low-volume dose (Type: EXPERIMENTAL): A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
- C1-INH - medium-volume dose (Type: EXPERIMENTAL): A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).

Based on this trial design, predict the completion outcome and termination type (if applicable).